Clinical Trial Update: A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection [Phase 3]

View source ↗

Summary

A global Phase 3 study evaluating osimertinib as adjuvant therapy in patients with EGFR-mutant stage IA2-IA3 non-small cell lung cancer after complete tumor res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING